Desloran

Quick links to important sections

Desloran

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Desloran

The following quick reference table summarizes the essential identity of the medication.

Property Description
Active ingredient Desloratadine (INN)
Form Oral solution, Film-coated tablet, Tablet
Pharmacological class Second-generation Antihistamine
Common use Relief of general allergy symptoms (e.g., hay fever, hives)
Origin Synthetic active metabolite of Loratadine

What Type of Medicine is Desloran (Desloratadine)?

Desloran is a commercial name for a product containing the active ingredient Desloratadine, which is classified as a second-generation antihistamine. This agent is primarily recognized as a highly selective H1-receptor antagonist. Desloratadine is specifically derived as the major active metabolite of the precursor drug, Loratadine.

This structural characteristic is vital, as it imparts low blood-brain barrier penetration, defining it as a non-sedating and long-acting agent. This profile is clinically recognized for its ability to provide sustained anti-allergic activity to manage allergy symptoms with minimal risk of central nervous system effects associated with older compounds.

Desloran Composition, Forms, and General Purpose

Desloran is formulated as a single active ingredient product designed for the oral route of administration. The medication is supplied in multiple pharmaceutical preparations, including the film-coated tablet, standard tablet, and oral solution forms. The composition consists of Desloratadine combined with appropriate solid excipients or an aqueous vehicle.

Its general therapeutic purpose is achieved through the mechanism of histamine H1 receptor blockade. The drug's profile is that of a nonsedating, long-acting H1 receptor antagonist. This sustained action ensures the systemic anti-allergic effect provides continuous relief from the common physical manifestations of hypersensitivity reactions throughout the day.

What side effects are possible with Desloran?

Possible Side Effects and Safety Information

The safety profile of Desloran (Desloratadine) is officially documented by government regulatory authorities, with adverse reactions formally classified by frequency and the body system affected. The data from clinical studies and post-marketing surveillance categorize most possible effects into Common or Very Rare tiers.


Frequency-Classified Adverse Reactions

The most frequently reported adverse reactions, classified as Common (occurring in at least 1 in 100 patients) are Headache, Fatigue, and Dry mouth.

Reactions categorized as Very Rare (occurring in fewer than 1 in 10,000 patients) include Tachycardia, Palpitations, Seizures, Hallucinations, Hepatitis, and temporary elevations in liver enzymes and bilirubin. Severe Hypersensitivity Reactions, such as Anaphylaxis and Angioedema, are also listed under the Very Rare classification.


System-Organ-Class Groupings

Adverse effects are grouped by the physiological system involved. These groupings include Nervous System Disorders (e.g., dizziness, somnolence, seizures), Gastrointestinal Disorders (e.g., vomiting, dyspepsia, abdominal pain), and Hepatobiliary Disorders (e.g., hepatitis, jaundice).


Population-Specific Considerations and Restrictions

Regulatory safety information addresses certain patient groups. Individuals with Renal or Hepatic Impairment may experience increased exposure to Desloratadine. In the Pediatric Population (ages 1 to 11), the safety profile is generally similar to adults, with reports including insomnia and psychomotor hyperactivity. A primary safety restriction is the contraindication against use in patients with known hypersensitivity to Desloratadine, any of its components, or to the precursor drug, Loratadine.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdosage with Desloran (Desloratadine) typically results in an adverse event profile similar to that observed at therapeutic doses, though the magnitude of these effects may be higher. The most commonly reported clinical manifestation documented in trials at higher doses is somnolence (drowsiness). Regarding cardiovascular safety, studies evaluating doses up to nine times the clinical dose found no evidence of QTc interval prolongation.

Immediate and urgent medical attention is required when severe clinical signs are present. Governmental guidance specifies that emergency services must be contacted immediately if a person experiences collapse, a seizure, trouble breathing, or cannot be awakened. In less severe cases where overdosage is suspected, contact with the Poison Control Helpline is advised. The official regulatory text for Desloratadine does not list a specific antidote.

Management involves standard procedural steps, including symptomatic and supportive treatment. Healthcare providers may consider measures to remove any unabsorbed active substance from the body. A key procedural consideration is that both Desloratadine and its active metabolite are not eliminated by hemodialysis. Regulatory documentation notes that the adverse event profile for overdosage in the paediatric population is similar to adults, but the effects may present with a higher magnitude.

Therapeutic Uses of Desloran

Desloran is generally used across therapeutic domains to provide sustained symptomatic relief in conditions driven by heightened allergic responses. It offers support that helps ease the overall burden of symptoms that may create noticeable interference with daily stability. The therapeutic indications are relief of symptoms associated with allergic rhinitis and urticaria.

This support addresses the common cluster of symptoms related to inflammatory states, including sneezing, runny nose, nasal stuffiness, and itching of the nose, eyes, or palate. For Chronic Idiopathic Urticaria (CIU), the use is relevant in conditions characterized by periods of heightened skin distress, such as recurrent hives (wheals) and intense itching (pruritus).

“The primary goal is often to provide supportive relief when symptoms interfere with routine activities, easing the overall symptom load.”

The primary therapeutic benefit is relevant for managing sustained symptomatic relief, assisting with maintaining functional stability and supporting general well-being during symptomatic periods. The medication is applicable in conditions presenting with two significant symptom-driven clinical presentations: allergic rhinitis (including both seasonal and perennial forms) and chronic idiopathic urticaria.

Quick Fact: Relief for Itching

Desloran is relevant for easing intense pruritus (itching) associated with chronic hives, a challenging symptom that creates noticeable physiological strain.

Eligibility and Restrictions for Use

Who can and cannot use Desloran? Official Regulatory Information

The eligibility profile for Desloran is defined by regulatory bodies through specific constraints concerning hypersensitivity, age, and physiological condition.

Eligibility Scope

Classification Population Status Defined by Official Labeling
Contraindicated Patients with known hypersensitivity to Desloratadine, Loratadine, or any excipients. Use absolutely prohibited
Recommended Adults and adolescents 12 years and older (tablets/solution); Children 6 months to 11 years (oral solution). Eligible for use
Not Recommended Pregnant women, breastfeeding mothers, and infants under 6 months of age. Avoid use due to risk or insufficient data

Condition-Specific Eligibility Rules

Official labeling specifies conditions where the medicine should be used with caution:

  • Severe Renal Impairment: Caution is required, and a dose adjustment is recommended in adults due to potential changes in drug exposure.
  • Hepatic Impairment: Caution is advised, and a dose adjustment is recommended in adults due to limited clinical data.
  • Seizure History: Caution is required in patients with a personal or familial history of seizures, as the medicine may increase seizure risk in susceptible individuals.

Pregnancy and Lactation Eligibility Status

Desloran is not recommended for use in pregnant women or during lactation, as the active substance is excreted into human milk, and its effect on the nursing infant is unknown.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Desloran has been studied for potential interactions with several substances. Regulatory data indicates that the following medicines, when co-administered, result in minor elevations of Desloran plasma concentrations ( C max and AUC):

Specific Interacting Medicines
Ketoconazole (an antifungal)
Erythromycin (a macrolide antibiotic)
Azithromycin (a macrolide antibiotic)
Fluoxetine (an SSRI)
Cimetidine (an H2-antagonist)

Official studies concluded that despite the observed changes in drug exposure, these increases were not clinically relevant to the safety profile, including no effect on electrocardiographic parameters (e.g., QTc interval). No medicinal product combinations are explicitly listed as contraindicated in the interaction section.


Food and Alcohol

The absorption of Desloran is not affected by food, meaning the medicine can be taken with or without meals. In clinical pharmacology trials, Desloran taken concomitantly with alcohol did not potentiate the performance-impairing effects of the alcohol. However, cases of alcohol intolerance and intoxication have been reported during post-marketing use, prompting regulatory cautions.


Population-Specific Considerations

Patients with severe renal impairment or hepatic impairment have significantly higher exposure (increased AUC and C max) to Desloran compared to healthy subjects. Additionally, individuals identified as poor metabolizers exhibit substantially higher Desloran concentrations due to a decreased ability to form the active metabolite, though official regulatory trials did not show an overall difference in safety compared to normal metabolizers.

Mechanism of Action

How Desloran Works: Mechanism of Action


Selective Control of the Histamine mathbfH1 Receptor

Desloratadine's primary action involves high affinity for the peripheral Histamine mathbfH1 receptor, where it functions as an inverse agonist. This mechanism stabilizes the receptor in an inactive state, halting histamine from increasing vascular permeability and contributing to tissue fluid leakage, thereby resulting in reduced histamine-mediated extravasation of fluid.


Modulating the Broader Inflammatory Cascade

Beyond H1 blockade, the molecule engages in the modulation of non-histaminergic pathways by suppressing the release of secondary inflammatory mediators, including specific cytokines and immune lipids, from immune cells. This action results in the modulation of the inflammatory system activity, which contributes to the modulation of the late-phase allergic response, resulting in a prolonged modulation of physiological activity.


Mechanism Defined by Peripheral Selectivity

The drug is chemically designed with poor lipophilicity, ensuring its activity is highly concentrated on peripheral systems like the skin and airways. This high concentration of activity in peripheral tissues enables targeted physiological modulation due to minimal interaction with central nervous system (CNS) H1 receptors.

Dosage and Administration Information

How to Use Desloran: Administration Guidelines

Desloran (desloratadine) administration is based on established guidelines for proper use. The medicine is approved for the oral route of administration and is available in forms including the film-coated tablet (5 mg strength) and the oral solution (0.5 mg/mL).


Standard Dosing and Frequency

The established regimen is a single, once-daily dose, leveraging the drug's long-acting profile. Dosing can occur with or without food.

Population Standard Dosing (Once Daily)
Adults and Adolescents (12 years and older) 5 mg (one tablet or 10 mL of oral solution)
Children (6 to 11 months) 1 mg (2 mL of oral solution)
Children (1 to 5 years) 1.25 mg (2.5 mL of oral solution)
Children (6 to 11 years) 2.5 mg (5 mL of oral solution)

Administration Context and Adjustments

When using the oral solution, the dose is measured using a calibrated device. For patients with severe hepatic impairment or renal impairment, the starting recommendation for adults is a modified dose of 5 mg every other day.

Treatment duration depends on the clinical presentation: for intermittent allergic rhinitis, treatment may be discontinued upon symptom resolution and re-initiated upon recurrence. Conversely, persistent allergic rhinitis and chronic urticaria often require continuous treatment during the symptomatic period.

Recent Clinical Evidence

Research evidence / Overview of Studies for Desloran

Evidence for Use in Allergic Rhinitis

The research base for Desloran includes a large volume of Randomized Controlled Trials (RCTs). These short-term, multi-center studies were used in research exploring how symptoms change over time and to assess outcomes related to physical discomfort associated with allergic rhinitis. Researchers examined patient-reported outcomes describing perceived discomfort, focusing on measured changes in both nasal and non-nasal symptoms. These studies were mainly conducted on adults and adolescents experiencing periods of heightened symptom activity.

The findings describe patterns observed in the studies related to a measured change in symptom scores and outcomes reflecting daily functioning and activity level. Data describes patterns observed related to how symptoms evolved in the observed populations during the short follow-up periods. However, the certainty around long-term outcomes are not fully established. The core efficacy research generally had follow-up durations that were limited to a few weeks, meaning limited information for long-term outcomes and maintenance of measured effects over many months.


Evidence for Use in Chronic Hives (Urticaria)

Research exploring symptoms associated with Chronic Idiopathic/Spontaneous Urticaria (CIU/CSU) was evaluated in multiple placebo-controlled RCTs. These studies explored outcomes linked to inflammatory or irritative states. Research examined outcomes related to physical discomfort, such as the severity of pruritus (itching) and the measurement of wheals (hives), in populations observed during the study period. Studies observed how symptoms evolved over defined time intervals, typically lasting up to six weeks.

The findings describe patterns observed in the studies related to measured changes in the intensity of itching and the physical presence of hives. Research also provides insight into short-term changes in functional measures like sleep interference. Data are still emerging regarding the long-term management of this condition, and there is limited information for long-term outcomes beyond the initial six weeks. Additionally, comparative evidence is lacking when trying to assess outcomes related to Desloran against all potential therapeutic alternatives.

Frequently Asked Questions (FAQ)

Common questions about Desloran (FAQ)


Q: How quickly does Desloran start to work after taking it?

According to official regulatory studies, the anti-allergic effects of Desloran can begin to be observed relatively quickly. Clinical pharmacology studies indicate that the antihistaminic effect can begin to be observed by one hour following a single dose.


Q: Which drug is Desloran derived from?

Desloratadine, the active ingredient in Desloran, is classified as an active metabolite. Official product information indicates that it is derived from the precursor drug, Loratadine.


Q: What specific symptoms of allergies does Desloran treat?

Desloran is approved for the relief of symptoms associated with allergic rhinitis, such as sneezing, runny nose, and itching. It is also used to relieve symptoms associated with urticaria (hives), including the reduction of itching and rash.


Q: What should I do if I miss a dose of Desloran?

As the drug is taken once a day, official patient information often suggests that if a dose is missed, it should be taken as soon as it is remembered, then the regular schedule should be resumed the following day. Taking a double dose to compensate for a missed dose is generally not advised.


Q: Does Desloran contain any gluten or lactose?

Official labeling lists lactose (a type of sugar) as one of the inactive ingredients (excipients) in the film-coated tablet formulation. Product labeling does not contain specific information about gluten content.


Q: Is Desloran available over the counter or do I need a prescription?

The regulatory status of Desloran varies by region. In certain areas, the 5 mg tablet is classified as a product not subject to medical prescription, which means it may be available over the counter in those regions.


Q: What is the maximum dose of Desloran I can take in a day?

The standard recommended dose for adults is one 5 mg tablet once daily. While studies have examined higher doses, the official product information reflects the standard recommended daily dose.

How should Desloran be stored and disposed of?

How to Store and Dispose of Desloran

Desloran (desloratadine) must be stored according to specific regulatory requirements to maintain its integrity and ensure safety.

Storage Requirements

Condition Requirement
Temperature Store at Controlled Room Temperature (20°C to 25°C or 68°F to 77°F).
Protection Keep in the original package to protect from moisture and excessive heat. The container must be kept tightly closed.
Child Safety Must be stored out of the sight and reach of children.

Disposal Instructions

Method Requirement
Environmental Rule Do not throw away any unused or expired medicine via wastewater or household waste (trash).
Official Procedure Ask a pharmacist or local authority for the correct way to dispose of the product, following local requirements.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Desloran found in:

A-Z Index: